Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines (ONC)
:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$170.99 - $313.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)403.05K
Market Cap
$37.09B
Enterprise Value$25.50B
Total Cash (Recent Filing)$2.52B
Total Debt (Recent Filing)$996.83M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 06, 2025EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding109,600,310
10 Day Avg. Volume452,263
30 Day Avg. Volume403,049
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue6.11
Enterprise Value/Gross Profit7.20
Enterprise Value/Ebitda-217.41
Forecast
1Y Price Target
$356.83Price Target Upside19.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBeOne Medicines delivered robust sales growth with a 41.4% increase in product revenue, driven by strong Brukinsa sales in the US and EU.
Future Growth PotentialKey upcoming catalysts include data readouts and potential global filings for new drug approvals, which could drive further growth.
Market PositionBrukinsa maintained its leadership position in the US market, with revenue growth significantly outpacing peers.
Bears Say
Clinical DevelopmentIt is too early to assess the efficacy of BeOne’s CDK4 inhibitor due to limited follow-up, making current response data inconclusive.
CompetitionPromising safety/tolerability shown for BGB-43395 (CDK4i), although efficacy numerically lower than PFE's (MP, Risinger) atirmociclib.
Product PerformanceSales of some of the licensed-in products like denosumab experienced a decline, highlighting areas of concern in product performance.
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $170.99 and its highest was $313.29 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $37.09B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Aug 06, 2025. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.322 by $0.588.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 0.61.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,600,310 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $0.91 in its last earnings report, beating expectations of $0.322. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$356.83 (19.63% Upside)
$356.83 (19.63% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 529.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.78%
12-Months-Change
Fundamentals
Return on Equity
-4.95%
Trailing 12-Months
Asset Growth
10.26%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines (ONC) is a biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the discovery and commercialization of novel small molecules designed to target specific biological pathways that are implicated in disease progression. With a commitment to advancing precision medicine, BeOne Medicines operates in the oncology sector, aiming to deliver targeted treatments that improve patient outcomes while minimizing side effects.
ONC Company Deck
ONC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant revenue growth, market leadership, and positive financial results. However, there are challenges related to competitive pricing and potential impacts from U.S. tariffs. The positive aspects significantly outweigh the challenges.View all ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
$356.83
▲(19.63% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---